Lilly sells legacy antibiotics in China; Daiichi picks a bispecific antibody in Zymeworks deal; Torrent recalls more than 1 million losartan bottles.
China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.
Sun Pharma has been issued a Form 483, Catalent is investing $14 million at a facility in Germany and more manufacturing news of note.
Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.
If a new draft law goes into effect, companies that make or sell fake vaccines could get fines of up to 30 times the value of the goods involved.
Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.
As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.
Smoke from a fire set off by welding sparks reportedly killed 10 workers and injured a dozen rescuers at a pharmaceutical plant in China.